Studies of Insulin and Glucagon Action in the Liver

ConditionDiabetes (DM)
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-45
SponsorDuke University

About this trial

This study examines how glucagon works to regulate glucose metabolism, based on new findings that suggest glucagon signaling in the liver has more than one role, and that these multiple roles can be opposing in nature. Understanding this biology provides an opportunity to develop new generations of glucagon-based drugs that target specific pathways, making them more effective at controlling blood glucose.

Participants will complete paired, 5-hour hyperinsulinemic glucose clamp visits in which they receive either glucagon or saline infusions while blood glucose is maintained and frequent blood samples are collected. The primary focus is whether coordinated glucagon and insulin signaling enhances hepatic insulin sensitivity.

Eligibility criteria

Qualifiers

Healthy adults age 18-45 years

Body Mass Index (BMI) < 27.0 kg/m²

Fasting plasma glucose ≤ 95 mg/dL or HbA1c ≤ 5.8% as measured at screening visit

Disqualifiers

Active medical disease: e.g. active infectious, inflammatory, neurodegenerative or mental health disorders

No personal history of diabetes or pancreatitis

No personal history of cardiac, gastrointestinal, renal or liver disease

No history of diabetes among any first-degree family members

Trial design

Treatments tested in this trial

  • Glucagon
  • Saline (placebo)

Treatment groups

40 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Duke University

Lead sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborator